Navigation Links
Ukrainian President Yushchenko: Pharmaceuticals 'Very Important'
Date:9/30/2008

- MaxWell Biocorporation Wins Presidential Support for Faster Registration

of Modern Medicines in Ukraine -

WASHINGTON, Sept. 30 /PRNewswire/ -- Dr. Kenneth Alibek, President and CEO of MaxWell Biocorporation, LLC, and Dr. Peter M. Leitner, President of MaxWell USA, LLC, participated today in a presidential breakfast to honor Ukrainian President Victor Yushchenko.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080624/NETU078LOGO )

The breakfast was hosted by the U.S.-Ukraine Business Council (USUBC). Nearly 100 senior business leaders, academics, and diplomats attended this invitation-only event, including three former United States ambassadors to Ukraine and the current US Ambassador to Kyiv William Taylor.

President Yushchenko discussed the current political and economic situation in Ukraine. The President repeated his strong support for Ukraine's further integration into the Euro-Atlantic community as shown by the recent events in Georgia, spoke about Ukraine's business environment, thanked the U.S. companies for their investments in Ukraine, and urged American investors to participate in even more projects in Ukraine.

Asking the first question, Dr. Alibek asked the Ukrainian President about prospects for ensuring timely registration and licensing procedures for foreign pharmaceutical companies with established production facilities in Ukraine, in order to expedite access to the latest medicines for the people of Ukraine. Companies are experiencing unnecessary and costly delays in this area, Dr. Alibek noted.

President Yushchenko stated that it is very important for Ukraine to have the latest and most effective pharmaceuticals. The Ukrainian President promised he would monitor this situation, and suggested to Dr. Alibek that he work closely with Mr. Yushchenko's staff to resolve this issue.

Later the same day, President Yushchenko met with President Bush at the White House, spoke at the National Press Club, and laid a wreath at the monument to famous Ukrainian poet Taras Shevchenko in Washington, DC.

About MaxWell

MaxWell Biocorporation (http://www.max-well.com) is a U.S.-based, privately-held international medical and pharmaceutical company with wholly owned subsidiaries and affiliates in the United States and Ukraine dedicated to increasing life expectancy and improving the quality of life of people in Ukraine and other underserved emerging healthcare markets in the former Soviet Union. MaxWell targets oncological, cardiological, chronic infectious and autoimmune disorders and diseases through the development, production, and introduction into clinical practice of sophisticated, high quality, and affordable off-patent generic biopharmaceutical and chemopharmaceutical medicines and the latest diagnostic and therapeutic methods. MaxWell = "Maximum Wellness."

"We Help You Live Longer"

Contact:

Alex Meerovich

A.Meerovich@max-well.com

202-454-3403 Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Kenneth Alibek https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78826 Peter Leitner https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78827


'/>"/>
SOURCE MaxWell Biocorporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. KGI Names Kerry Howell Vice President for Advancement
2. Vical Names Andrew de Guttadauro Vice President, Corporate Development
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
5. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
6. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
7. CryoLife Names Philip Theodore as Vice President, General Counsel
8. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
9. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that in a published evaluation of multiple immunoassay-based threat detection technologies ... of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to ...
(Date:2/23/2017)... 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology ... today announced that Linda Marbán, Ph.D, president and chief executive ... Cowen and Company 37th Annual Health ... Boston, MA 29th ... PT (12:00 pm ET) Dana Point, CA ...
(Date:2/22/2017)... Kan. , Feb. 22, 2017  Aratana Therapeutics, Inc. ... development and commercialization of innovative biopharmaceutical products for companion animals, ... 2017 at 8:30 a.m. ET to discuss financial results from ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... CINCINNATI , Feb. 22, 2017 Scientists ... drives inflammation and organ damage in Gaucher and maybe ... fewer risks and lower costs than current therapies. ... Children,s Hospital Medical Center , which also included investigators ... , report their data Feb. 22. The study ...
Breaking Biology Technology:
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
Breaking Biology News(10 mins):